a2 China Infant Formula Defies Downturn with Strong Sales; Major Moves Ahead

Summary

a2 Milk Company's global revenue for H1 FY2025 (to 31 December 2024) was NZD 893.8 million (approx. RMB 3.72 billion), up 10.1% year-on-year. Revenue from China and other Asian markets reached NZD 614.2 million (approx.

RMB 2.56 billion), accounting for 68.7% of global revenue, an increase of 11.8%. The market share of Chinese-label a2 Platinum infant formula hit a record high of 5.3%, with total infant formula sales of NZD 604.7 million, up 7.2%, achieving double-digit growth in China and maintaining a top-five brand position. The company announced its first dividend policy, distributing 67% of net profit.

CEO David Bortolussi raised FY2025 revenue guidance to low-to-mid single-digit growth. Future plans include expanding the family nutrition strategy, registering more Chinese-label infant formula products, establishing an R&D centre in Shanghai, and exploring local production partnerships.

Commentary

a2 Milk Company's financial results offer multiple insights for New Zealand small and medium-sized enterprises (SMEs). On the positive side, a2's counter-trend growth in China demonstrates strong demand for premium New Zealand dairy, especially in infant formula, where Chinese-label products achieved record market share. This suggests SMEs could focus on Chinese consumers' emphasis on brand traceability and quality, considering entry via cross-border e-commerce or local channel partnerships.

Meanwhile, a2's plan to build an R&D centre in Shanghai and explore local production may signal future manufacturing in China, posing a potential challenge for SME suppliers reliant on New Zealand origin – they need to strengthen differentiation, such as organic or grass-fed attributes. On the other hand, a2's first dividend and raised guidance indicate robust cash flow, but China's infant formula market faces intensifying competition and higher registration thresholds under new regulations. SMEs should cautiously assess their resources and avoid blind following.

Conclusion: a2's performance and initiatives show China still offers a window of opportunity, but the rewards tend to favour companies with technological barriers and brand equity; smaller firms should target niche segments.

Keywords: a2 Milk Company, infant formula, China market, revenue growth, market share, a2 Platinum, Chinese label, R&D centre, localisation, dividend

Summary in Chinese | 摘要

a2牛奶公司2025财年上半年（截至2024年12月31日）全球营收8.938亿新西兰元（约37.2亿元），同比增长10.1%。中国及其他亚洲市场营收6.142亿新西兰元（约25.6亿元），占全球68.7%，同比增长11.8%。中文a2至初婴配粉市场份额创历史新高至5.3%，整体婴配粉销售6.047亿新西兰元，同比增长7.2%，在中国市场逆势双位数增长，保持前五大品牌。

公司首次推出股息政策，将净利润67%用于分红。CEO David Bortolussi上调2025财年营收指引至低到中位数的两位数增长。未来计划包括：全家营养战略扩容、推进更多中文标签婴配粉注册、在上海建立研发中心、探索本土化生产合作。

Commentary in Chinese | 评论

a2牛奶公司这份财报对新西兰中小企业主有多重启示。正面看，a2在中国市场的逆势增长证明高端新西兰乳品仍有强劲需求，特别是婴配粉领域，中文标签产品市场份额创新高。这提示中小企业可关注中国消费者对品牌溯源和品质的重视，考虑通过跨境电商或与本地渠道合作进入市场。

同时，a2计划在上海建研发中心和探索本土化生产，可能意味着未来部分产品将在中国制造，这对依赖新西兰原产地的中小供应商构成潜在挑战——它们需要强化自身差异化优势，如有机、草饲等特色。另一方面，a2首次分红并上调营收指引，显示其现金流充沛，但中国婴配粉市场整体竞争加剧，新政下注册门槛提高。中小企业应谨慎评估自身资源，避免盲目跟风。

结语：a2的业绩和举措表明，中国市场仍存在窗口期，但红利更倾向于有技术壁垒和品牌积淀的企业，小企业需聚焦细分赛道。

关键词: a2牛奶公司, 婴配粉, 中国市场, 营收增长, 市场份额, 至初奶粉, 中文标签, 研发中心, 本土化, 分红

Source: None